All In Biotech

Drug Trial Radar · NCT07760246

A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart

A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group Design Trial With Moxifloxacin as Positive Control in a Nested Crossover to Evaluate the Effects of Multiple Doses of Verducatib (BI 1291583) on Cardiac Safety Parameters in Healthy Male and Female Trial Participants

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

56

Actual

Start

Aug 20, 2026

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters

Conditions

  • Healthy

Interventions

  • VerducatibDrug

    Verducatib

  • MoxifloxacinDrug

    Moxifloxacin

  • Placebo resembling VerducatibDrug

    Placebo resembling Verducatib

  • Placebo resembling MoxifloxacinDrug

    Placebo resembling Moxifloxacin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QT-interval corrected for heart rate, e.g. using the method of Fridericia change from baseline (ΔQTcF), paired with the verducatib plasma concentrationsTime frame: Up to day 31

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRS Clinical Research Services Mannheim GmbH

    Mannheim, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.